Health Care · Medicinal Chemicals & Botanical Products · Nasdaq · CIK 1386570 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $3.32Day +3.11%Mkt cap $256MP/E (FY) 16.1×1Y −65.2%Off 52W high −70.6%Vol (1Y) 49.0%
Daily closing price, split-adjusted to the current basis; 1.3y shown of 333 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.0% of sh out |
| Days to cover6.5d |
| 13F net flow (QoQ)+3.28% |
| Top-10 13F concentration56.8% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)16.1× |
| Sales (TTM)$130.4M |
| Earnings (TTM)$18.6M |
| ROE28.3% |
| Net margin13.4% |
| Sales growth 3Y21.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−47.8% |
| 1Y−65.2% |
| Since incept. (ann.)−46.2% |
Total return through 2026-07-30 · series begins 2025-03-19. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)49.0% |
| Ann. volatility (3Y)55.7% |
| Sharpe (1Y)−2.01 |
| Sharpe (3Y)−0.87 |
| Max drawdown (1Y)−68.9% |
| Max drawdown (3Y)−77.9% |
| Beta (3Y vs SPY)1.88 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 3.9M | $17M | 4.83% | −5.0% |
| SteelPeak Wealth, LLC | 3.4M | $15M | 4.21% | new |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.4M | $10M | 2.97% | +47.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $9M | 2.68% | new |
| Tieton Capital Management, LLC | 2.0M | $9M | 2.53% | +23.3% |
| Qube Research & Technologies Ltd | 1.7M | $8M | 2.14% | +61.5% |
| UBS Group AG | 1.4M | $6M | 1.76% | −0.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $6M | 1.68% | +3.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $0.07 | +16.7% | $31.5M | +3.3% |
| 2025-12-31 | 2026-03-04 | — | — | $33.8M | +16.2% |
| 2025-09-30 | 2025-11-04 | $0.05 | +150.0% | $34.0M | +32.9% |
| 2025-06-30 | 2025-08-06 | $0.04 | — | $31.1M | +36.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Consumer Products 75% · Ingredients 22% · Analytical Reference Standards And Services 2%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
